St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia

oncodaily - St. Jude shared a post on X: “St. Jude researchers and collaborators identified RBM5 as a key driver of leukemia caused by changes in the KMT2A gene through its interaction with […]

AI Summary: St. Jude investigators report that RBM5 is a central driver in a form of childhood leukemia, revealing how the RNA-binding protein helps sustain malignant cells and interact with MYC pathways. The finding opens a plausible route to target an otherwise “undruggable” axis, offering a new precision strategy for high-risk pediatric leukemia.

#pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #pediatriconcology #genetics

Two cellular components unlock maturation in human leukemia cells, study finds

5 wks / medicalxpress

Leukemia Diagnosis: Every Step From First Symptoms to Treatment and Beyond

5 wks / oncodaily

Aishee Pal Sadhu: Philadelphia Chromosome Positivity Should Not Be Treated as a Binary Label Before CAR-T

5 wks / oncodaily

St. Jude Researchers and Collaborators Identified RBM5 as a Key Driver of Leukemia

6 wks / oncodaily

Targeting RBM5 may help disrupt 'undruggable' MYC in childhood leukemia

6 wks / medicalxpress